BALB/c-Il4^tm2Nnt/J

Stock number: 002496
Product name: IL-4-
Research areas: Cancer Research, Immunology, Inflammation and Autoimmunity Research

Description

Mice homozygous for Il4^tm2Nnt have significantly reduced levels of IgGl and IgE and reduced ability to produce Th2-derived cytokines. Mice are susceptible to infection by Leishmania major.

Detailed description

Mice homozygous for the Il4^tm2Nnt targeted mutation are viable and fertile. T and B cell development is normal but IgGl and IgE levels and the ability of homozygous mutant mice to produce Th2-derived cytokines are significantly reduced. Susceptible to infection by Leishmania major despite deficiency in IL4.

Development

This strain was developed by Dr. Nancy Noben-Trauth and Dr. Birgit Ledermann at Sandoz Pharma Ltd. in Basel, Switzerland. A BALB/c-derived ES cell line was used.

Allele

Symbol: Il4^tm2Nnt
Name: targeted mutation 2, Nancy Noben-Trauth
MGI accession ID: MGI:1857195
Generation method: Targeted
Attributes: Null/Knockout
Marker symbol: Il4
Marker name: interleukin 4
Chromosome: 11
Strain of origin: BALB/cJ
Molecular note: A neomycin resistance cassette was inserted into exon 3 of the gene.
General note: Susceptibility to Leishmania major in BALB/c mice has been ablated by introduction of a null mutant of the Il4 gene (J:35236), but in that study the introduced mutant came from a strain 129 background, and 129 is resistant to L. major infection. In mice carrying one of Noben-Trauth's null mutants, targeted in BALB/c embryonic stem cells, the loss of Il4 expression did not remove susceptibility to infection (J:31486).